This is not the most recent version of the article. View current version (28 FEB 2014)

Intervention Protocol

Blood pressure lowering efficacy of non-selective beta blockers for primary hypertension

  1. Gavin WK Wong1,*,
  2. Alexandra Laugerotte2,
  3. James M Wright1

Editorial Group: Cochrane Hypertension Group

Published Online: 8 OCT 2008

Assessed as up-to-date: 17 JUN 2010

DOI: 10.1002/14651858.CD007452


How to Cite

Wong GWK, Laugerotte A, Wright JM. Blood pressure lowering efficacy of non-selective beta blockers for primary hypertension (Protocol). Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD007452. DOI: 10.1002/14651858.CD007452.

Author Information

  1. 1

    University of British Columbia, Department of Anesthesiology, Pharmacology and Therapeutics, Vancouver, BC, Canada

  2. 2

    University of British Coulumbia, Anesthesiology, Pharmacology & Therapeutics, Vancouver, BC, Canada

*Gavin WK Wong, Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada. gavin.wong@ti.ubc.ca.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 8 OCT 2008

SEARCH

This is not the most recent version of the article. View current version (28 FEB 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Primary objective

To quantify the dose-related effects of various doses and types of non-selective beta adrenergic receptor blockers on systolic and diastolic blood pressure versus placebo in patients with primary hypertension.

Secondary objectives

  1. To determine the effects of non-selective beta adrenergic receptor blockers on variability of blood pressure.
  2. To determine the effects of non-selective beta adrenergic receptor blockers on pulse pressure.
  3. To quantify the dose-related effects of non-selective beta adrenergic receptor blockers on heart rate.
  4. To quantify the effects of non-selective beta adrenergic receptor blockers in different doses on withdrawals due to adverse events.